Ipca Laboratories

IPCALAB.NS

Mumbai, India· Est. 1949

ipca.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IPCALAB.NS · Stock Price

INR 1,560.10+198.30 (+14.56%)

Market Cap: $4.2B

Historical price data

Market Cap: $4.2BPipeline: 31 drugsPatents: 17Founded: 1949HQ: Mumbai, India

Overview

Ipca Laboratories is a mission-driven, fully integrated global pharmaceutical company dedicated to advancing healthcare through quality, affordable medicines. Its strategic achievements include establishing world-leading API manufacturing capabilities, securing approvals from stringent global regulators, and building a robust international footprint. The company's core strategy hinges on vertical integration for cost and supply chain control, therapeutic area dominance, and a growing R&D focus on novel drugs and biologics to drive future growth.

Anti-malarialsAnalgesics/PainAnti-inflammatoryCardiovascularAnti-diabeticsAnti-infectivesHair Care

Technology Platform

A multi-platform R&D engine encompassing chemical process research, biosimilar development (mAbs), bio-processing & metabolic engineering, and novel drug discovery (NCEs), supported by advanced analytical research and IP management.

Pipeline

31 drugs in pipeline

Drug	Indication	Stage
Lamotrigine Tablets 25 mg + Lamotrigine	Fed	Phase 1
Lamotrigine Tablets 25 mg + Lamotrigine	Fasting State	Phase 1
Metformin Hydrochloride Extended-Release Tablets USP 750 mg ...	Fasting	Phase 1
Levocetirizine Dihydrochloride tablets 5 mg + Levocetirizine...	Fed	Phase 1
Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride	Fasting State	Phase 1

Funding History

IPOUndisclosedUndisclosedSep 15, 1995

FDA Approved Drugs

ETODOLACANDAAug 1, 2024

ETODOLACANDAMay 1, 2024

ONDANSETRONANDAOct 30, 2023

Opportunities

Ipca is poised to capture growth from biosimilars, novel drug candidates like AT-10 for cardiovascular disease, and the commercialization of repurposed drugs for unmet needs like Diabetic Foot Ulcer.

Its leadership in fermentation-based APIs also positions it to benefit from global supply chain diversification away from single sources.

Risk Factors

Key risks include regulatory compliance failures at manufacturing sites, clinical trial setbacks for its novel pipeline, and intense pricing pressure in the global generics market which could erode formulation margins despite vertical integration.

Competitive Landscape

Ipca faces competition from large Indian and Chinese API manufacturers, global generic pharma companies, and biotech firms in its innovative pursuits. Its vertical integration and niche dominance in anti-malarials provide defensibility, but execution in novel drug development is critical to long-term differentiation.